Last €8.94 EUR
Change Today +0.07 / 0.79%
Volume 3.1K
ALMED On Other Exchanges
Symbol
Exchange
EN Paris
As of 11:35 AM 07/30/14 All times are local (Market data is delayed by at least 15 minutes).

medicrea international (ALMED) Snapshot

Open
€8.87
Previous Close
€8.87
Day High
€8.94
Day Low
€8.76
52 Week High
06/6/14 - €10.60
52 Week Low
01/13/14 - €7.05
Market Cap
75.8M
Average Volume 10 Days
2.5K
EPS TTM
€0.05
Shares Outstanding
8.5M
EX-Date
--
P/E TM
190.2x
Dividend
--
Dividend Yield
--
Current Stock Chart for MEDICREA INTERNATIONAL (ALMED)

Related News

No related news articles were found.

medicrea international (ALMED) Related Businessweek News

No Related Businessweek News Found

medicrea international (ALMED) Details

Medicrea manufactures and distributes implants in France. It offers PASS range, a polyaxial spine system; PASS LP, a thoraco-lumbar fixation system; LigaPASS, a band connector for posterior thoracic fixation use to de-rotate and correct spinal deformities, such as scoliosis; and PASS ANT, a polyaxial low profile thoraco-lumbar system for anterior approach. The company also provides a range of implants for the cervical spine, including C-JAWS, an anterior cervical spinal fixation system; IMPIX C, a sterile PEEK Optima cervical inter body device; Impix C+, a sterile PEEK Optima cervical inter body device that is prefilled with bone substitutes; and MANTA, a sterile PEEK Optima cervical inter body device, which is preassembled on holder and delivers with disposable instrumentation kit. Its implants for cervical spine also include MANTA +, a sterile PEEK Optima cervical inter body device, which is prefilled with bone substitutes, as well as preassembled on disposable holder and delivered with disposable instrumentation kit; GRANVIA C, a MRI compatible ceramic cervical disc; and LaminoJAWS, a cervical laminoplasty implant with a posterior approach. In addition, the company offers implants for the thoracic and lumbar spine, such as IMPIX-L, a sterile PEEK Optima lumbar inter body device for posterior approach; IMPIX ALIF, a sterile PEEK Optima lumbar inter body device for anterior approach; and OSMOSYS, a macro porous bone substitute. Its implants are designed to treat scoliosis, degenerative deformation, trauma, and tumors; and are used in various traditional and advanced surgical techniques, such as minimally-invasive surgery. The company was founded in 1990 and is based in Lyon, France.

109 Employees
Last Reported Date: 04/25/14
Founded in 1990

medicrea international (ALMED) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

medicrea international (ALMED) Key Developments

The MEDICREA Group Announces Sales Results for the First Half of the Fiscal Year Ended June 30, 2014

The MEDICREA Group announced sales results for the first half of the fiscal year ended June 30, 2014. For the period, the company reported sales of EUR 11.9 million compared to EUR 11.9 million a year ago. The group recorded a significant increase in its sales in the United States, its priority development market. In dollars, U.S. sales increased 18% compared with the first half of 2013, with a new monthly invoicing record of $2.4 million in June. As of June 30, 2014, U.S. sales accounted for 56% of the group's total sales.

Medicrea Launches New Spinal Osteosynthesis Rod System in Europe

Medicrea has launched the UNiD, a patient-specific spinal osteosynthesis rod system, in Europe. Spinal surgeons in France have successfully implanted the customized UNiD rods into 43 patients with severe spinal deformities. These customized implants, which are specifically pre-contoured using x-rays and proprietary software, enable the surgeons to perfectly execute their surgical plans and accurately restore the sagittal alignment specific to each patient. The UNiD system includes a software application and a real-time support team that provide a seamless process by which surgeons preoperatively analyze, design, and order the patient-specific rods. Until now, surgeons had no alternative but to use a bending device supplied in all instrument kits to bend the rods manually. This manual rod-contouring process involves estimating the curve in a very empirical manner using pre-operative X-rays displayed on a wall in the operating room. With UNiD, surgeons can now be certain of implanting spinal fusion rods that are precisely adapted to the patient because UNiD rods are personalized and accurately curved using a design established by the surgeon during the pre-operative planning phase. Due to the UNiD's interface, with the free SURGIMAP software, spine surgeons have access to the most recent scientific data available on the parameters necessary to determine and restore sagittal alignment for each patient. The UNiD rods, customized for each patient, are pre-contoured using a controllable and reproducible industrial process. This eliminates the intraoperative use of a bending device, which creates indentations, or notches, in the rod. Such notches are an acknowledged cause of rods breaking postoperatively, which can occur in patients - especially adults with severe spinal deformities. By eliminating the manual bending of rods during surgery, surgeons can significantly reduce operating time. This is an additional benefit, since infection rates and the quality of a patient's recovery are directly linked to the duration of the surgical procedure. As soon as the surgeon validates the rod's design in the SURGIMAP UNiD application, Medicrea precisely manufactures the implantable rod and delivers it within one week.

The MEDICREA Group Reports Sales Results for the First Quarter Ended March 31, 2014; Provides Sales Guidance for the Second Half of 2014

The MEDICREA Group reported sales results for the first quarter ended March 31, 2014. For the quarter, the company reported sales were EUR 5,376,000 against EUR 5,405,000 a year ago. The Group has continued its development in the United States with sales up 18% in dollars in the first quarter of 2014 compared with the same period of 2013. In France, over the quarter the Group recorded sales growth of close to 40% due to the extension of its product range and its referencing in new hospitals. The strengthening of the sales teams in the United States and France, as well as the recent recruitments aimed at strengthening the international sales team, will see their full effects over the second half of 2014. Moreover, the Group is about to launch a major product innovation that should allow it to move up to the next level and accelerate its sales growth, primarily in the United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALMED:FP €8.94 EUR +0.07

ALMED Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ALMED.
View Industry Companies
 

Industry Analysis

ALMED

Industry Average

Valuation ALMED Industry Range
Price/Earnings 100.0x
Price/Sales 3.2x
Price/Book 5.6x
Price/Cash Flow 156.3x
TEV/Sales 3.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDICREA INTERNATIONAL, please visit www.medicrea.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.